Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2015

View Archived Issues

Inotek Pharmaceuticals begin dosing in pivotal phase III study of trabodenoson

OMT and Armo BioSciences enter into anti-PD-1 antibody agreement

Kolltan Pharmaceuticals reports efficacy data from phase Ib KTN-3379 trial

New phase IIa study investigates simeprevir, odalasvir and AL-335 treatment regimen in HCV

First clinical results presented for novel radiotracer [123/131I]IMAZA

[111In]CP04 could represent a step forward in medullary thyroid carcinoma imaging

Arisaph starts phase II trial of niacin analogue ARI-3037-MO in patients with NAFLD or NASH

HKU and international research teams identify novel PARP-1 complex

DSMB recommends continuation of phase III study of Vyxeos for AML

Luc Therapeutics licenses NMDA modulators for depression to Novartis

Fecal microbiome transplant shows favorable safety profile in HIV-infected subjects

FDA grants orphan drug designation to receptor-Fc fusion protein for the treatment of ovarian cancer

Responses seen with avelumab in trials in mesothelioma, gastric/gastroesophageal junction cancer

Novel NNT gene mutation linked to left ventricular noncompaction

First-in-human results reveal activity of SYD-985 in patients with solid tumors

Curis expands cancer drug pipeline

FDA grants orphan drug designation and fast track status to resunab for cystic fibrosis

FDA approves Coagadex for hereditary factor X deficiency

Tris Pharma's Dyanavel XR approved in U.S. for ADHD in children

Synta terminates phase III trial of ganetespib in NSCLC

InterMune discloses antifibrotic pyridinones

Taisho Pharmaceutical patents orexin receptor antagonists

Sumitomo Dainippon Pharma describes alpha7 nAChR positive allosteric modulators

Eicosis develops soluble epoxide hydrolase inhibitors

Medshine Discovery reports hedgehog signaling pathway inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...